Hemodialysis Technology Company Diality Names Robert Funari to its Board of Directors

2023-05-31
高管变更并购
IRVINE, Calif.--(BUSINESS WIRE)-- Diality Inc., a medical technology company developing a smart, flexible hemodialysis platform, today announced the appointment of healthcare veteran Robert Funari to its board of directors. Funari has spent nearly 50 years in the healthcare industry in public and privately held companies, in both services and medical devices. He has served as president and CEO of several companies, including Syncor International (acquired by Cardinal Health) and Crescent Healthcare, and as chairman or director of several companies, including Patient Care America and Beckman Coulter. He was chairman of hemodialysis technology company NxStage Medical until its 2019 acquisition by Fresenius Medical Care. At Baxter International, he held a variety of roles for nearly 20 years, ultimately serving as president of its Pharmaseal division. “Robert has an outstanding, half-century record of bringing his knowledge and strategic thinking to bear on the constantly evolving healthcare market,” said Osman Khawar, MD, CEO of Diality. “His insights will be invaluable as we prepare to bring our new hemodialysis system to market to empower kidney care providers while prioritizing patient care and quality of life.” Diality’s hemodialysis system is designed to be versatile enough for any care setting. Its compact footprint together with an intuitive user interface are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility. “Diality’s novel approach to developing an extremely flexible hemodialysis system interested me from the start,” added Funari. “I look forward to working with the strong leadership team Osman has assembled to help bring its mission of improving lives impacted by kidney disease to fruition.” Diality also announced that Aaron Mishkin is leaving its board of directors. “We thank Aaron for his dedicated service at Diality, and wish him well in his future endeavors,” Khawar said. About Diality Diality is a medical technology company developing a smart hemodialysis platform designed to be as capable and flexible as in-center treatment in an easy-to-use device that’s intended to be safe to operate in any environment. It offers versatility to enable healthcare providers to tailor treatment to each patient’s specific needs. The Diality system’s compact footprint and mobility are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility. To learn more, please visit or find us on LinkedIn. Disclaimer: This product is not yet available for use in the EU or US and is pending CE Mark and submission and clearance by the United States Food and Drug Administration. Performance claims referenced are development goals.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。